Clinical Trials Browser

Phase 1/2 × bemcentinib × Other hematologic neoplasm × Clear all

NCT02488408 2024-12-19

A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS

Phase 1/2 Completed

122 enrolled 29 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute